Cypherpunk Technologies (CYPH) Competitors

$1.09 +0.05 (+4.81%)

As of 05/19/2026 04:00 PM Eastern

CYPH vs. CCCC, BNTC, AGMB, CABA, and CLLS

Should you buy Cypherpunk Technologies stock or one of its competitors? MarketBeat compares Cypherpunk Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cypherpunk Technologies include C4 Therapeutics (CCCC), Benitec Biopharma (BNTC), AgomAb Therapeutics (AGMB), Cabaletta Bio (CABA), and Cellectis (CLLS). These companies are all part of the "pharmaceutical products" industry.

How does Cypherpunk Technologies compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

C4 Therapeutics presently has a consensus target price of $7.75, suggesting a potential upside of 149.20%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe C4 Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

C4 Therapeutics has a beta of 2.77, meaning that its stock price is 177% more volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market.

Cypherpunk Technologies has lower revenue, but higher earnings than C4 Therapeutics. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	9.57	-$104.99M	-$1.19	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Cypherpunk Technologies has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. Cypherpunk Technologies' return on equity of -48.33% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, C4 Therapeutics had 8 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 11 mentions for C4 Therapeutics and 3 mentions for Cypherpunk Technologies. C4 Therapeutics' average media sentiment score of 0.31 beat Cypherpunk Technologies' score of -1.12 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cypherpunk Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

C4 Therapeutics beats Cypherpunk Technologies on 11 of the 15 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Cypherpunk Technologies has lower revenue, but higher earnings than Benitec Biopharma. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	$80K	4,602.90	-$37.92M	-$1.14	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Benitec Biopharma presently has a consensus target price of $27.00, suggesting a potential upside of 151.87%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Benitec Biopharma is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Benitec Biopharma had 2 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 5 mentions for Benitec Biopharma and 3 mentions for Cypherpunk Technologies. Benitec Biopharma's average media sentiment score of 0.58 beat Cypherpunk Technologies' score of -1.12 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cypherpunk Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Benitec Biopharma has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market.

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Benitec Biopharma's return on equity of -34.82% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

Summary

Benitec Biopharma beats Cypherpunk Technologies on 12 of the 14 factors compared between the two stocks.

How does Cypherpunk Technologies compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

In the previous week, Cypherpunk Technologies had 1 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 3 mentions for Cypherpunk Technologies and 2 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.00 beat Cypherpunk Technologies' score of -1.12 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cypherpunk Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

AgomAb Therapeutics presently has a consensus target price of $32.00, suggesting a potential upside of 204.47%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe AgomAb Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

AgomAb Therapeutics' return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Cypherpunk Technologies	N/A	-48.33%	-42.21%

30.5% of Cypherpunk Technologies shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Summary

AgomAb Therapeutics beats Cypherpunk Technologies on 6 of the 9 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

In the previous week, Cabaletta Bio had 4 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 7 mentions for Cabaletta Bio and 3 mentions for Cypherpunk Technologies. Cabaletta Bio's average media sentiment score of 0.70 beat Cypherpunk Technologies' score of -1.12 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cypherpunk Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Cabaletta Bio currently has a consensus target price of $15.50, suggesting a potential upside of 374.01%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Cabaletta Bio is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

30.5% of Cypherpunk Technologies shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Cabaletta Bio has a beta of 3.18, meaning that its stock price is 218% more volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market.

Cypherpunk Technologies' return on equity of -48.33% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

Summary

Cabaletta Bio beats Cypherpunk Technologies on 8 of the 13 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Cellectis?

Cellectis (NASDAQ:CLLS) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Cellectis presently has a consensus target price of $6.75, suggesting a potential upside of 85.95%. Given Cellectis' stronger consensus rating and higher possible upside, equities analysts clearly believe Cellectis is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cellectis has a beta of 2.94, indicating that its stock price is 194% more volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market.

Cypherpunk Technologies has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Cypherpunk Technologies' return on equity of -48.33% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

63.9% of Cellectis shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cypherpunk Technologies had 2 more articles in the media than Cellectis. MarketBeat recorded 3 mentions for Cypherpunk Technologies and 1 mentions for Cellectis. Cellectis' average media sentiment score of 0.34 beat Cypherpunk Technologies' score of -1.12 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cypherpunk Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Cypherpunk Technologies has lower revenue, but higher earnings than Cellectis. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	4.58	-$67.59M	-$0.67	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Summary

Cellectis beats Cypherpunk Technologies on 11 of the 16 factors compared between the two stocks.

Get Cypherpunk Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYPH vs. The Competition

Export

Metric	Cypherpunk Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$110.72M	$3.25B	$6.25B	$12.23B
Dividend Yield	N/A	2.34%	2.80%	5.32%
P/E Ratio	-54.47	18.52	20.79	25.05
Price / Sales	N/A	270.32	531.21	72.69
Price / Cash	N/A	124.58	43.09	54.25
Price / Book	1.38	6.60	9.81	6.83
Net Income	$4.82M	$24.18M	$3.55B	$335.69M
7 Day Performance	4.81%	-3.74%	-2.12%	-2.15%
1 Month Performance	25.47%	-7.95%	-4.14%	-2.47%
1 Year Performance	186.84%	50.32%	28.34%	27.13%

Cypherpunk Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYPH Cypherpunk Technologies	0.4093 of 5 stars	$1.09 +4.8%	N/A	+162.8%	$110.72M	N/A	N/A	40	Negative News Earnings Report
CCCC C4 Therapeutics	1.8415 of 5 stars	$3.63 -1.4%	$7.75 +113.5%	+101.9%	$405.47M	$34.86M	N/A	150	Earnings Report
BNTC Benitec Biopharma	2.0165 of 5 stars	$11.85 +1.7%	$27.00 +127.8%	-23.3%	$400.23M	$80K	N/A	20	Earnings Report
AGMB AgomAb Therapeutics	N/A	$11.04 -1.3%	$32.00 +189.9%	N/A	$400.06M	N/A	N/A	62	Short Interest Increase
CABA Cabaletta Bio	2.5156 of 5 stars	$3.61 +0.6%	$17.00 +370.9%	+70.3%	$399.66M	N/A	N/A	50	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYPH) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cypherpunk Technologies (CYPH) Competitors

CYPH vs. CCCC, BNTC, AGMB, CABA, and CLLS

How does Cypherpunk Technologies compare to C4 Therapeutics?

Summary

How does Cypherpunk Technologies compare to Benitec Biopharma?

Summary

How does Cypherpunk Technologies compare to AgomAb Therapeutics?

Summary

How does Cypherpunk Technologies compare to Cabaletta Bio?

Summary

How does Cypherpunk Technologies compare to Cellectis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH vs. The Competition

Cypherpunk Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cypherpunk Technologies (CYPH) Competitors

CYPH vs. CCCC, BNTC, AGMB, CABA, and CLLS

How does Cypherpunk Technologies compare to C4 Therapeutics?

Do analysts rate CCCC or CYPH?

Which has more volatility & risk, CCCC or CYPH?

Which has higher earnings and valuation, CCCC or CYPH?

Is CCCC or CYPH more profitable?

Do institutionals & insiders hold more shares of CCCC or CYPH?

Does the media prefer CCCC or CYPH?

Summary

How does Cypherpunk Technologies compare to Benitec Biopharma?

Which has preferable valuation & earnings, BNTC or CYPH?

Do analysts recommend BNTC or CYPH?

Does the media refer more to BNTC or CYPH?

Which has more volatility & risk, BNTC or CYPH?

Do insiders & institutionals have more ownership in BNTC or CYPH?

Is BNTC or CYPH more profitable?

Summary

How does Cypherpunk Technologies compare to AgomAb Therapeutics?

Does the media favor AGMB or CYPH?

Do analysts prefer AGMB or CYPH?

Is AGMB or CYPH more profitable?

Do institutionals and insiders hold more shares of AGMB or CYPH?

Which has better earnings & valuation, AGMB or CYPH?

Summary

How does Cypherpunk Technologies compare to Cabaletta Bio?

Does the media favor CABA or CYPH?

Do analysts recommend CABA or CYPH?

Do institutionals & insiders hold more shares of CABA or CYPH?

Which has higher valuation and earnings, CABA or CYPH?

Which has more risk & volatility, CABA or CYPH?

Is CABA or CYPH more profitable?

Summary

How does Cypherpunk Technologies compare to Cellectis?

Do analysts rate CLLS or CYPH?

Which has more risk and volatility, CLLS or CYPH?

Is CLLS or CYPH more profitable?

Do insiders & institutionals hold more shares of CLLS or CYPH?

Does the media favor CLLS or CYPH?

Which has stronger earnings & valuation, CLLS or CYPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH vs. The Competition

Cypherpunk Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools